Higuchi Hisashi, Kamata Mitsuhiro, Sugawara Yuka, Yoshida Keizo
Omagari City Hospital, Iida, Japan.
Clin Neuropharmacol. 2005 Jul-Aug;28(4):191-2. doi: 10.1097/01.wnf.0000171248.89726.2f.
A 34-year-old man presented with severe refractory depression. He had failed to respond to various antidepressants, augmentation therapy with lithium carbonate, and modified electroconvulsive therapy. Switching from amoxapine 150 mg/day to selegiline 7.5 mg/day, a selective monoamine oxidase type-B inhibitor, produced a dramatic reduction in hypobulia and lassitude, leading to a complete remission of all depressive symptoms. The patient reverted to his former position at work after an interval of approximately 3 years. Although the biologic basis of the antidepressant effect of selegiline in this patient is unknown, it is suggested that the enhancement of dopaminergic neurotransmission or elevation of brain-derived neurotrophic factor levels in the brain by administration of selegiline is involved in the recovery of this patient from severe refractory depression. This report indicates the antidepressant effect of selegiline in a refractory depressed patient.
一名34岁男性患有严重难治性抑郁症。他对各种抗抑郁药、碳酸锂增效治疗以及改良电休克治疗均无反应。将每日150毫克的阿莫沙平换成每日7.5毫克的司来吉兰（一种选择性单胺氧化酶B型抑制剂）后，患者的意志缺乏和倦怠症状显著减轻，所有抑郁症状完全缓解。大约3年后，该患者恢复了原来的工作岗位。虽然司来吉兰对该患者产生抗抑郁作用的生物学基础尚不清楚，但推测司来吉兰通过增强多巴胺能神经传递或提高大脑中脑源性神经营养因子水平，使该患者从严重难治性抑郁症中康复。本报告表明了司来吉兰对难治性抑郁症患者的抗抑郁作用。
